Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 18/20 | 0.71 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21359581 | 1.00 | OGA (0.71) | OGAOPRK1SMN1; SMN2 | |
| SCHEMBL21359533 | 0.94 | OGA (0.63) | OGAOPRK1 | |
| SCHEMBL21370256 | 0.94 | OGA (0.63) | OGAOPRK1 | |
| SCHEMBL21359477 | 0.90 | OGA (0.70) | OGAOPRK1 | |
| SCHEMBL21370250 | 0.90 | OGA (0.70) | OGAOPRK1 | |
| SCHEMBL21359483 | 0.89 | OGA (0.64) | OGAOPRK1SMN1; SMN2 | |
| SCHEMBL21359564 | 0.89 | OGA (0.69) | OGAOPRK1SMN1; SMN2 | |
| SCHEMBL21369538 | 0.89 | OGA (0.69) | OGAOPRK1SMN1; SMN2 | |
| SCHEMBL21369416 | 0.89 | OGA (0.74) | OGAOPRK1 | |
| SCHEMBL28583580 | 0.89 | OGA (0.74) | OGAOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118955490-A | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112218863-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 比奥根MA公司 | 2024-07-12 | — | — | CN | disclosed |
| EP-4186899-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2023-05-31 | — | — | EP | disclosed |
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2023-04-20 | — | — | US | disclosed |
| EP-3765458-B1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20210040080-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2021-02-11 | — | — | US | disclosed |
| CN-112218863-A | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranosidase inhibitors | 比奥根MA公司 | 2021-01-12 | — | — | CN | disclosed |
| WO-2019178191-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. (US) | 2019-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230117898-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | MGAT3, ST3GAL3, ST6GAL1 | OGA 26/4885OPRK1 2094/4885SMN1; SMN2 3815/4885 |
| US-20210040080-A1 | O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLYCOPYRANOSIDASE INHIBITORS | MGAT3, ST6GAL1, ST3GAL3 | OGA 32/4885OPRK1 2112/4885SMN1; SMN2 3481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.